Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple.

Patricio Duarte,Natalia Schutz,Paola Ochoa,Sebastian Yantorno,Sergio Orlando,Sergio Lopresti,Soledad Zabaljauregui,Florencia Aizpurua,Claudia Shanley,Elvira Giannini,Gonzalo Garate,Cecilia Foncuberta,Jorge Milone,Dardo Riveros,Dorotea Fantl

Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma múltiple.

2021

Patricio Duarte
Natalia Schutz
Paola Ochoa
Sebastian Yantorno
Sergio Orlando
Sergio Lopresti
Soledad Zabaljauregui
Florencia Aizpurua
Claudia Shanley
Elvira Giannini
Gonzalo Garate
Cecilia Foncuberta
Jorge Milone
Dardo Riveros
Dorotea Fantl

We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting. In addition, we evaluated adverse even...

Keywords:

Refractory Multiple Myeloma
Retrospective cohort study
Medicine
Oncology
real world outcomes
Multiple myeloma
Lenalidomide
Dexamethasone
relapsed refractory
Latin Americans
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations